Samsung BiologicsLtd Balance Sheet Health
Financial Health criteria checks 6/6
Samsung BiologicsLtd has a total shareholder equity of ₩10,328.3B and total debt of ₩1,468.4B, which brings its debt-to-equity ratio to 14.2%. Its total assets and total liabilities are ₩16,342.9B and ₩6,014.5B respectively. Samsung BiologicsLtd's EBIT is ₩1,324.3B making its interest coverage ratio -91.7. It has cash and short-term investments of ₩1,568.6B.
Key information
14.2%
Debt to equity ratio
₩1.47t
Debt
| Interest coverage ratio | -91.7x |
| Cash | ₩1.57t |
| Equity | ₩10.33t |
| Total liabilities | ₩6.01t |
| Total assets | ₩16.34t |
Recent financial health updates
Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?
May 27
These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Jan 18
Recent updates
Samsung Biologics Co.,Ltd.'s (KRX:207940) 26% Share Price Surge Not Quite Adding Up
Jul 29Does Samsung BiologicsLtd (KRX:207940) Have A Healthy Balance Sheet?
May 27What Samsung Biologics Co.,Ltd.'s (KRX:207940) P/E Is Not Telling You
Apr 14With EPS Growth And More, Samsung BiologicsLtd (KRX:207940) Is Interesting
Mar 01These 4 Measures Indicate That Samsung BiologicsLtd (KRX:207940) Is Using Debt Reasonably Well
Jan 18What Kind Of Shareholders Own Samsung Biologics Co.,Ltd. (KRX:207940)?
Dec 28How Much Is Samsung Biologics Co.,Ltd. (KRX:207940) CEO Getting Paid?
Dec 08Did You Miss Samsung BiologicsLtd's (KRX:207940) Impressive 112% Share Price Gain?
Nov 18Financial Position Analysis
Short Term Liabilities: A207940's short term assets (₩5,431.4B) exceed its short term liabilities (₩4,034.1B).
Long Term Liabilities: A207940's short term assets (₩5,431.4B) exceed its long term liabilities (₩1,980.4B).
Debt to Equity History and Analysis
Debt Level: A207940 has more cash than its total debt.
Reducing Debt: A207940's debt to equity ratio has reduced from 19.8% to 14.2% over the past 5 years.
Debt Coverage: A207940's debt is well covered by operating cash flow (112.6%).
Interest Coverage: A207940 earns more interest than it pays, so coverage of interest payments is not a concern.